1. Home
  2. PTGX vs PLUS Comparison

PTGX vs PLUS Comparison

Compare PTGX & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTGX
  • PLUS
  • Stock Information
  • Founded
  • PTGX 2006
  • PLUS 1990
  • Country
  • PTGX United States
  • PLUS United States
  • Employees
  • PTGX N/A
  • PLUS N/A
  • Industry
  • PTGX Biotechnology: Pharmaceutical Preparations
  • PLUS Retail: Computer Software & Peripheral Equipment
  • Sector
  • PTGX Health Care
  • PLUS Technology
  • Exchange
  • PTGX Nasdaq
  • PLUS Nasdaq
  • Market Cap
  • PTGX 2.8B
  • PLUS 2.6B
  • IPO Year
  • PTGX 2016
  • PLUS 1996
  • Fundamental
  • Price
  • PTGX $47.91
  • PLUS $96.76
  • Analyst Decision
  • PTGX Strong Buy
  • PLUS Hold
  • Analyst Count
  • PTGX 7
  • PLUS 1
  • Target Price
  • PTGX $52.83
  • PLUS $90.00
  • AVG Volume (30 Days)
  • PTGX 450.1K
  • PLUS 100.1K
  • Earning Date
  • PTGX 11-08-2024
  • PLUS 11-05-2024
  • Dividend Yield
  • PTGX N/A
  • PLUS N/A
  • EPS Growth
  • PTGX N/A
  • PLUS N/A
  • EPS
  • PTGX 2.75
  • PLUS 4.08
  • Revenue
  • PTGX $319,120,000.00
  • PLUS $2,195,665,000.00
  • Revenue This Year
  • PTGX $400.33
  • PLUS $5.69
  • Revenue Next Year
  • PTGX N/A
  • PLUS $4.68
  • P/E Ratio
  • PTGX $17.54
  • PLUS $24.00
  • Revenue Growth
  • PTGX 125.73
  • PLUS 0.56
  • 52 Week Low
  • PTGX $13.76
  • PLUS $53.54
  • 52 Week High
  • PTGX $48.89
  • PLUS $102.99
  • Technical
  • Relative Strength Index (RSI)
  • PTGX 60.40
  • PLUS 52.65
  • Support Level
  • PTGX $45.33
  • PLUS $96.35
  • Resistance Level
  • PTGX $48.89
  • PLUS $99.25
  • Average True Range (ATR)
  • PTGX 1.28
  • PLUS 2.09
  • MACD
  • PTGX 0.11
  • PLUS -0.38
  • Stochastic Oscillator
  • PTGX 77.11
  • PLUS 28.23

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

About PLUS ePlus inc.

ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.

Share on Social Networks: